Safety and Efficacy of Intrauterine Biological Barrier on Postoperative Adhesion After Hysteroscopic Adhesiolysis

Inclusion Criteria: * （1）Age, yr20-40 (including boundary value), Female * （2）Normal ovarian reserve function (FSH\<10U/ml，AMH\>2ng/ml) * （3）Who suffered from moderate to severe intrauterine adhesions (AFS ≥ 5 points) diagnosed by hysteroscopy, and prepared to be treated by Hysteroscopic adhesiolysis * （4）Both husband and wife have fertility intention during treatment * （5）Accept to treatment and follow-up visits, Sign the ICF Exclusion Criteria: * （1）Severe systemic diseases, contraindications of surgical and cycle * （2）Inflammation of reproductive tract, genital tuberculosis, pelvic infection, tumor of reproductive organs * （3）Systemic diseases cause uterine bleeding * （4）Allergic to hyaluronic acid or components * （5）Allergic to swine sources medical device, or refuse to swine sources medical device for religious, ethnic and other reasons * （6）Insufficient uterine cavity volume after Hysteroscopic adhesiolysis to place Intrauterine Biological Barrier or inject Intrauterine Adhesion Barrier Gel * （7）Involved other clinical trial before Hysteroscopic adhesiolysis in 3 months or during the trail * （8）Unable to tolerate anesthesia * （9）Estrogen medicine was taken within 30 days of Hysteroscopic adhesiolysis * （10）Other inadequacy patient assessed by the researchers